B. Riley analyst Kalpit Patel raised the firm’s price target on Kymera Therapeutics to $31 from $16 and keeps a Neutral rating on the shares. Management provided insights into the proteome study and the firm walks away with “some initial confidence” to include the STAT6 and TYK2 programs into its model, though it keeps a Neutral rating on shares given the lack of significant clinical catalysts and valuation.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on KYMR:
- Kymera Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Provides a Business Update
- Kymera Therapeutics sees cash runway into 1H27
- Kymera Therapeutics reports Q4 EPS (25c), consensus (40c)
- Kymera Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results on February 22
- Kymera Therapeutics initiated with a Peer Perform at Wolfe Research
